ReviewCurrent oncology (Toronto, Ont.)2015
Management of egfr tki-induced dermatologic adverse events.
Review in Current oncology (Toronto, Ont.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Control Trial to Compare Doxycycline to Isotretinoin for the Treatment of Acneiform Eruptions in Cancer Patients on Tyrosine Kinase Inhibitors
Prophylactic TCM for Mitigation of EGFR-TKI Related Dermatological Adverse Effect
Who cites it
26 citing papers in PubMed, 78 citations in OpenAlex.
- Prophylactic treatment of dacomitinib-induced skin toxicities in epidermal growth factor receptor-mutated non-small-cell lung cancer: A multicenter, Phase II trial.Cancer medicine · 2023Trial
- Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).Lung cancer (Amsterdam, Netherlands) · 2017Trial
- A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2016Trial
- Efficacy of Prophylactic Traditional Chinese Medicine on Skin Toxicity of Afatinib inIntegrative cancer therapiesTrial
- Safety Profile and Tumor Response of EGFR-TKIs in Clinical Practice: A Real-World Study in Thailand.Journal of clinical medicine · 2026Article
- Role of solute carrier transporters in the biodistribution and toxicity of chemotherapeutic drugs.Pharmacological reviews · 2026Review
- Global pharmacovigilance analysis of dermatologic toxicity in EGFR-TKI-treated NSCLC: a cross-database real-world study.Frontiers in pharmacology · 2026Article
- Efficacy and safety of EGFR-TKI for EGFR-mutated NSCLC: systematic review and network meta-analysis.International journal of clinical and experimental pathology · 2025Review
- An Analysis of Risk Factors for the Development of Acneiform Eruptions in Patients on Monoclonal Antibody Epidermal Growth Factor Receptor Inhibitors.Journal of cutaneous medicine and surgery · 2023Article
- Evaluation of factors affecting epidermal growth factor receptor tyrosine kinase inhibitor-induced hepatotoxicity in Japanese patients with non-small cell lung cancer: a two-center retrospective study.Journal of pharmaceutical health care and sciences · 2022Article
- Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies.Frontiers in oncology · 2022Review
- Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review.International journal of molecular sciences · 2021Review
- Differential effects of epidermal growth factor receptor inhibitors in a single patient with neuropathic pain.BMJ case reports · 2021Article
- Relationship between adverse events associated with lenvatinib treatment for thyroid cancer and patient prognosis.Molecular and clinical oncology · 2021Article
- Osimertinib-Associated Toxic Epidermal Necrolysis in a Lung Cancer Patient Harboring an EGFR Mutation-A Case Report and a Review of the Literature.Medicina (Kaunas, Lithuania) · 2020Review
- Observational
- FDA- and EMA-Approved Tyrosine Kinase Inhibitors in AdvancedBiomolecules · 2019Review
- Patient voice on management of facial dermatological adverse events with targeted therapies: a qualitative study.Journal of patient-reported outcomes · 2019Article
- Multi-disciplinary proactive follow-up algorithm for patients with advanced NSCLC receiving afatinib.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019Article
- Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.The oncologist · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeting the epidermal growth factor receptor (egfr) pathway has become standard practice for the treatment of advanced non-small-cell lung cancer. Compared with chemotherapy, egfr tyrosine kinase inhibitors (tkis) have been associated with improved efficacy in patients with an EGFR mutation. Together with the increase in efficacy comes an adverse event (ae) profile different from that of chemotherapy. That profile includes three of the most commonly occurring dermatologic aes: acneiform rash, stomatitis, and paronychia. Currently, no randomized clinical trials have evaluated the treatments for the dermatologic aes that patients experience when taking egfr tkis. Based on the expert opinion of the authors, some basic strategies have been developed to manage those key dermatologic aes. Those strategies have the potential to improve patient quality of life and compliance and to prevent inappropriate dose reductions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.